Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetic Interaction of Lotiglipron with Dabigatran and Rosuvastatin in Overweight or Obese Adults
NCT05788328Phase 1Terminated
- Sponsor
- Pfizer
- Start
- Mar 2023
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lotiglipron in obesity and Overweight, sponsored by Pfizer. Primary endpoints: Area Under the Concentration-Time Curve From Time Zero to Infinity for Total Dabigatran at 48 hours, Area Under the Concentration-Time Curve From Time Zero to Last Measurable Concentration for Total Dabigatran at 48 hours and 2 more. Started Mar 2023; status: terminated.
02
Drugs
lotiglipron
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT05788328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05788328.